← Back to Screener
bioAffinity Technologies, Inc. Warrant (BIAFW)
Price$0.20
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (4W)-54.51%
VGM Score23.44
All Metrics
Price vs S&P 500 (YTD)-56.80%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.00M
52-Week High$0.81
13-Week Price Return-20.41%
3-Month Return Std Dev389.31%
Year-to-Date Return-42.86%
5-Day Price Return-9.13%
Month-to-Date Return-39.39%
Price vs S&P 500 (13W)-29.28%
Beta4.31x
52-Week Low$0.05
mGradeD
vgmGradeD
Show chart for
Industry Peers — R&D — Physical Sciences(15)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BIAFWbioAffinity Technologies, Inc. Warrant | — | — | D | $0.20 |
| IQVIQVIA Holdings Inc. | C | B | B | $186.82 |
| INCYIncyte Genomics Inc | C | A | B | $95.59 |
| MEDPMedpace Holdings, Inc. Common Stock | D | A | B | $451.47 |
| ICLRIcon Plc | C | C | B | $138.03 |
| CRLCharles River Laboratories International, Inc. | D | D | B | $182.07 |
| ABSIAbsci Corporation Common Stock | F | F | A | $6.52 |
| NRCNRC Health Common Stock | D | D | B | $20.25 |
| OABIOmniAb, Inc. Common Stock | D | C | A | $2.61 |
| MXCTMaxCyte, Inc. Common Stock | C | D | C | $1.22 |
| ONMDOneMedNet Corp Class A Common Stock | D | C | C | $0.78 |
About
bioAffinity Technologies develops noninvasive diagnostic tests for early-stage cancer, particularly lung cancer, and targeted cancer therapeutics. Its proprietary CyPath Lung test uses technology that preferentially targets cancer cells to enable early-stage lung cancer detection without invasive procedures. The company addresses a significant clinical need for improved early cancer diagnosis and treatment options.